The current data indicate that BRAF mutation in NSCLC is not indicative of any correlation with improved survival or any benefit to chemotherapy in clinical settings, except for the fact that 20–30% of patients with the V600E mutation are non-smokers, whereas the non-V600E subtypes are chain smokers [20, 24, 69–74]. Here, BRAF is linked to non-small cell lung carcinoma.